A study commissioned by the Association of the British Pharmaceutical Industry (ABPI) was published this week in the journal Current Medical Research and Opinion. It suggests that there is now greater transparency for industry-sponsored clinical trials. This would be good. We are asking the ABPI about the methodology, the exclusion of incomplete trials from the denominator, and decisions to exclude trials on combination products and vaccines and those conducted by ‘third party institutes’.